Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
- PMID: 21382020
- DOI: 10.1111/j.1365-2141.2011.08615.x
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
Abstract
There is little information published comparing peripheral blood stem cells (PBSC) with bone marrow (BM) as the stem cell source in the long-term outcome in recipients of T-cell depleted (TCD) unrelated donor (UD) transplants. We present retrospective outcome data on 306 recipients of myeloablative, human leucocyte antigen-matched UD allografts using pre-transplant in-vivo Alemtuzumab. Transplants were performed between 2000 and 2007 for chronic myeloid leukaemia in first chronic phase and acute leukaemia in first or second complete remission; 184 patients received BM and 122 PBSC. The median age was 28·9 years (<1-58) and the median follow-up was 48 months. Overall survival at 8 years was 53%. The incidence of acute graft-versus-host disease (GvHD) was significantly higher in PBSC (65%) than BM recipients (49%; P=0·012). This represented only grade 1 GvHD with no difference in grade II-IV aGvHD (BM 23% PBSC 24%). The incidence of chronic GvHD, either overall (BM 47%, PBSC 49%) or extensive (BM 15%, PBSC 13%) was not increased with PBSC. The incidence of relapse, non-relapse mortality and survival were not significantly different. Whilst accepting the limitations of retrospective analyses, we suggest the increased risk of GvHD in recipients of PBSC in T-replete transplants is offset by in-vivo Alemtuzumab, and that either stem cell source can be used with good outcomes in this setting.
© 2011 Blackwell Publishing Ltd.
Similar articles
-
Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.Klin Padiatr. 2005 May-Jun;217(3):135-41. doi: 10.1055/s-2005-836509. Klin Padiatr. 2005. PMID: 15858704
-
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.Haematologica. 2007 Nov;92(11):1513-8. doi: 10.3324/haematol.11353. Haematologica. 2007. PMID: 18024400
-
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.Biol Blood Marrow Transplant. 2005 Feb;11(2):85-92. doi: 10.1016/j.bbmt.2004.09.010. Biol Blood Marrow Transplant. 2005. PMID: 15682068 Clinical Trial.
-
Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation.Transfus Med Rev. 2019 Jan;33(1):43-50. doi: 10.1016/j.tmrv.2018.11.003. Epub 2018 Nov 12. Transfus Med Rev. 2019. PMID: 30528986 Review.
-
Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation.Blood. 1995 Jul 15;86(2):813-8. Blood. 1995. PMID: 7606012 Review.
Cited by
-
NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD.Eur J Immunol. 2018 Feb;48(2):316-329. doi: 10.1002/eji.201747134. Epub 2017 Oct 27. Eur J Immunol. 2018. PMID: 28944953 Free PMC article.
-
T cell depletion in paediatric stem cell transplantation.Clin Exp Immunol. 2013 May;172(2):139-47. doi: 10.1111/cei.12004. Clin Exp Immunol. 2013. PMID: 23574311 Free PMC article. Review.
-
Thyroid dysfunction from antineoplastic agents.J Natl Cancer Inst. 2011 Nov 2;103(21):1572-87. doi: 10.1093/jnci/djr373. Epub 2011 Oct 18. J Natl Cancer Inst. 2011. PMID: 22010182 Free PMC article. Review.
-
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.Biol Blood Marrow Transplant. 2016 Feb;22(2):385-390. doi: 10.1016/j.bbmt.2015.09.004. Epub 2015 Sep 9. Biol Blood Marrow Transplant. 2016. PMID: 26363443 Free PMC article.
-
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.Biol Blood Marrow Transplant. 2013 May;19(5):804-11. doi: 10.1016/j.bbmt.2013.02.009. Epub 2013 Feb 14. Biol Blood Marrow Transplant. 2013. PMID: 23416855 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical